LifeSci Capital initiated coverage of Zymeworks (ZYME) with an Outperform rating and $30 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks: Hold Rating Amid Financial Challenges and Upcoming Catalysts
- Zymeworks price target raised to $13 from $12 at H.C. Wainwright
- Zymeworks price target raised to $19 from $18 at Citi
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes